🟢 Neurosense Therapeutics is trading 8% up in pre-market; no clear catalyst identified

Neurosense Therapeutics is trading at $2.66, up 8.13% in pre-market; no clear catalyst has been identified for the October 26 move.

• The latest company-specific news found was an October 19 patent application for PrimeC in traumatic brain injury. It predates the move and does not establish its cause.
• Provided broader market indicators show only modest gains and do not clearly explain the move.